Advanced Biomed Inc. Common Stock (ADVB) - Net Assets
Based on the latest financial reports, Advanced Biomed Inc. Common Stock (ADVB) has net assets worth $288.07K USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($333.01K) and total liabilities ($44.94K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Advanced Biomed Inc. Common Stock's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $288.07K |
| % of Total Assets | 86.51% |
| Annual Growth Rate | 37.38% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 117.77 |
Advanced Biomed Inc. Common Stock - Net Assets Trend (2021–2025)
This chart illustrates how Advanced Biomed Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. See Advanced Biomed Inc. Common Stock (ADVB) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Advanced Biomed Inc. Common Stock (2021–2025)
The table below shows the annual net assets of Advanced Biomed Inc. Common Stock from 2021 to 2025. For live valuation and market cap data, see Advanced Biomed Inc. Common Stock stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $3.48 Million | +109.08% |
| 2024-06-30 | $1.66 Million | +27.40% |
| 2023-06-30 | $1.31 Million | -62.61% |
| 2022-06-30 | $3.49 Million | +257.66% |
| 2021-06-30 | $976.24K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Advanced Biomed Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1380174600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $21.64K | 0.62% |
| Other Comprehensive Income | $1.34 Million | 38.58% |
| Other Components | $21.35 Million | 613.86% |
| Total Equity | $3.48 Million | 100.00% |
Advanced Biomed Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Advanced Biomed Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Titan Pharmaceuticals Inc
NASDAQ:TTNP
|
$6.13 Million |
|
Eo2 Société Anonyme
PA:ALEO2
|
$6.13 Million |
|
Masivo Silver Corp
V:MASS
|
$6.14 Million |
|
INC S.A.
WAR:INC
|
$6.14 Million |
|
Scandinavian Brake Systems A/S
CO:SBS
|
$6.12 Million |
|
H3 Energy Limited
AU:H3E
|
$6.12 Million |
|
Craneware Plc
LSE:CRW
|
$6.12 Million |
|
enVVeno Medical Corp
NASDAQ:NVNO
|
$6.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Advanced Biomed Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,663,258 to 3,477,564, a change of 1,814,306 (109.1%).
- Net loss of 101,524 reduced equity.
- Other comprehensive income increased equity by 218,346.
- Other factors increased equity by 1,697,484.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-101.52K | -2.92% |
| Other Comprehensive Income | $218.35K | +6.28% |
| Other Changes | $1.70 Million | +48.81% |
| Total Change | $- | 109.08% |
Book Value vs Market Value Analysis
This analysis compares Advanced Biomed Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.65x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-06-30 | $0.90 | $5.10 | x |
| 2022-06-30 | $3.23 | $5.10 | x |
| 2023-06-30 | $1.21 | $5.10 | x |
| 2024-06-30 | $1.54 | $5.10 | x |
| 2025-06-30 | $3.21 | $5.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Advanced Biomed Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -2.92%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.87x
- Recent ROE (-2.92%) is above the historical average (-96.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -188.19% | 0.00% | 0.00x | 1.03x | $-1.93 Million |
| 2022 | -115.35% | 0.00% | 0.00x | 1.92x | $-4.38 Million |
| 2023 | -9.31% | 0.00% | 0.00x | 3.52x | $-252.08K |
| 2024 | -167.28% | 0.00% | 0.00x | 2.68x | $-2.95 Million |
| 2025 | -2.92% | 0.00% | 0.00x | 1.87x | $-449.28K |
Industry Comparison
This section compares Advanced Biomed Inc. Common Stock's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $728,478,914
- Average return on equity (ROE) among peers: -109.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Advanced Biomed Inc. Common Stock (ADVB) | $288.07K | -188.19% | 0.16x | $6.13 Million |
| Agilent Technologies Inc (A) | $4.63 Billion | -22.30% | 0.77x | $35.96 Billion |
| Applied DNA Sciences Inc (APDN) | $8.97 Million | -77.97% | 0.43x | $3.99 Million |
| Biodesix Inc (BDSX) | $20.88 Million | -205.65% | 3.66x | $79.44 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.07 Million | 0.00% | 0.00x | $3.77 Million |
| Biocept Inc. (BIOCQ) | $8.86 Million | -362.16% | 2.48x | $525.00 |
| BillionToOne, Inc. Class A Common Stock (BLLN) | $480.11 Million | 1.55% | 0.32x | $4.36 Billion |
| Burning Rock Biotech Ltd (BNR) | $1.16 Billion | -83.85% | 0.37x | $63.90 Million |
| CareDx Inc (CDNA) | $261.33 Million | -72.81% | 0.79x | $1.13 Billion |
| Check Cap Ltd (CHEK) | $5.91 Million | -165.47% | 0.34x | $9.42 Million |
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagul… Read more